Clinical trial / 2021
Resveratrol supplementation improved cognitive performance, cerebrovascular function, and insulin sensitivity in postmenopausal women.
In a 24-month crossover trial, 125 postmenopausal women aged 45-85 years took 75 mg trans-resveratrol or placebo twice daily for 12 months, followed by the alternative treatment for 12 months. Compared to placebo, resveratrol resulted in a significant 33% improvement in overall cognitive performance (Cohen's d = 0.170, P = 0.005). Resveratrol also improved resting mean cerebral blood flow velocity (d = 0.275, P = 0.001), cerebrovascular responsiveness to hypercapnia (d = 0.307, P = 0.027) and cognitive stimuli (d = 0.259, P = 0.032), fasting insulin (d = 0.174, P = 0.025), and insulin resistance index (d = 0.102, P = 0.034). Women aged 65 and older showed a relative improvement in verbal memory compared to those younger than 65 years.
- Study type
- Randomized, double-blind, placebo-controlled crossover trial
- Who was studied
- 125 postmenopausal women aged 45-85 years
- What was measured
- Cognition, cerebrovascular function in the middle cerebral artery, and cardio-metabolic markers
THE PAPER
Long-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women: A 24-month randomised, double-blind, placebo-controlled, crossover study.
Thaung Zaw JJ, Howe PR, Wong RH. Clin Nutr, 2021.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.